EFX Gains From Proprietary Data & AI Products Growth Amid High Rates

Equifax reported Q2 2026 adjusted EPS of $2.25, up 12.5% year over year and 1.8% above consensus, while revenue rose 10.6% to $1.7 billion. International revenue increased 8% reported, and the company expects more than $1 billion in 2026 free cash flow; it launched 54 AI-enabled products in the first half. Offsetting these positives, management expects 2026 mortgage originations to decline by low single digits as the 30-year mortgage rate reached about 6.6%, while short-term debt and current maturities rose to $1.41 billion from $1.04 billion at year-end 2025.

Analysis

The key debate is whether Equifax can convert product launches into durable pricing and share gains quickly enough to offset mortgage cyclicality—not the count of AI products. Proprietary data may improve retention and product differentiation, but launch volume and the Vitality Index are company indicators, not proof of incremental revenue or returns. Watch organic growth and margins by product/segment, plus evidence that adoption is broadening beyond existing customers.

Near term, mortgage volumes and funding costs are the pressure points. Higher rates can suppress bureau inquiry volumes while commercial-paper reliance makes Equifax more exposed to a disruption in short-term funding markets; expected free cash flow is a buffer, not a guarantee. Over 1–3 months, mortgage-rate direction and cash conversion are likely more price-relevant than the longer-dated AI rollout. Over 6–18 months, successful integration of Círculo and international margin progress could diversify earnings, while a weak housing cycle would test the claimed growth mix.

A contrarian read: reported mortgage revenue growth may obscure weaker underlying transaction volumes, while AI optimism could be overcapitalized before unit economics are visible. Conversely, a sustained high-rate environment need not invalidate the data-product thesis if non-mortgage organic growth and margins hold. Equifax’s data-bureau competitors, including TransUnion, face similar housing exposure; relative performance should hinge on execution and valuation, neither established here. CBIZ and EVERTEC are not direct comparables to Equifax based on the information provided.

Key Decisions for Investors

• Avoid chasing the AI narrative on product-launch counts alone. Treat EFX as a watch/hold pending reported organic growth and margin evidence attributable to newer products; falsifier: deceleration in non-mortgage growth or margin deterioration despite continued launches.
• Consider a conditional relative-value trade: long EFX versus TransUnion only if Equifax demonstrates superior non-mortgage organic growth and cash conversion over the next 1–2 reports. No valuation or performance data are supplied to justify initiating the pair now; exit the thesis if that operating outperformance fails to emerge.
• Monitor mortgage rates and originations over the next 1–3 months. A renewed rise in mortgage rates alongside weaker originations would argue against adding EFX on headline revenue growth; easing rates plus improving transaction volumes would reduce this near-term overhang.
• Track commercial-paper balances, revolver usage, free-cash-flow delivery, and leverage through year-end. A funding-market shock or cash conversion below guidance would raise balance-sheet risk and could crowd out buybacks or M&A; sustained cash generation and declining short-term borrowing would falsify that concern.